Research Papers:

Cryoablation with drug-loaded bead embolization in the treatment of unresectable hepatocellular carcinoma: safety and efficacy analysis

Jian-Ying Zeng, Xiang-Hao Piao _, Zhong-Yuan Zou, Qing-Feng Yang, Zi-Lin Qin, Ji-Bing Chen, Liang Zhou, Li-Zhi Niu and Jian-Guo Liu

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:7557-7566. https://doi.org/10.18632/oncotarget.24029

Metrics: PDF 1898 views  |   HTML 2092 views  |   ?  


Jian-Ying Zeng1, Xiang-Hao Piao2, Zhong-Yuan Zou2, Qing-Feng Yang2, Zi-Lin Qin3, Ji-Bing Chen1, Liang Zhou4, Li-Zhi Niu4 and Jian-Guo Liu4

1Central Laboratory, Affiliated Fuda Cancer Hospital, Jinan University, Guangzhou 510665, P.R. China

2Department of Intervention, Affiliated Fuda Cancer Hospital, Jinan University, Guangzhou 510665, P.R. China

3School of Medicine, Jinan University, Guangzhou 510632, P.R. China

4Department of Surgical Oncology, Affiliated Fuda Cancer Hospital, Jinan University, Guangzhou 510665, P.R. China

Correspondence to:

Xiang-Hao Piao, email: [email protected]

Keywords: hepatocellular carcinoma; transarterial chemoembolization; cryoablation; hepasphere microsphere; doxorubicin

Received: November 02, 2017    Accepted: January 03, 2018    Published: January 08, 2018


This study aimed to explore the efficacy and safety of drug-eluting bead (DEB) embolization (DEB-TACE) when combined with cryoablation in the treatment of unresectable hepatocellular carcinoma (HCC). The study was a single-center randomized controlled trial comprised of 60 patients with HCC conducted between August 2015 and October 2017. The patients were randomly divided into two groups: DEB-TACE combined with cryoablation (DEB-TACE-Cryo group) or cryoablation alone (Cryo group). Inter-group differences in overall survival, progression-free survival, and adverse reactions were assessed. The operative success rates were 82.7% and 77.4% in the DEB-TACE-Cryo group and Cryo group, respectively, with no operative mortality. The overall survival and progression-free survival in the DEB-TACE-Cryo group were significantly higher than those in the Cryo group (16.8 months vs.13.4 months, P = 0.0493; 8.1 months vs. 6.0 months, P = 0.0089, respectively). The postoperative complications in the two groups were rated as grade 1 or grade 2, according to guidelines set by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE V4.0). We demonstrated that DEB-TACE combined with cryoablation was effective, well tolerated, and had a low complication rate. Therefore, this combination therapy may be a better choice for the treatment of unresectable hepatocellular carcinoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24029